Competing interests
R.T., S.A.H.
CHRONIC LIVER DISEASE
S.A.H. reports grant/research support from 89 Bio, Boehringer Ingelheim, Akero, Altimmune, Axcella, Corcept, Cymabay, Enyo, Galectin, Galmed, Genentech, Genfit, Gilead, Hepion, Hightide, Intercept, Madrigal, Metacrine, NGM Bio, NorthSea, Poxel, Sagimet and Viking; advisory/consulting fees from Akero, Altimmune, AstraZeneca, Axcella, Chronic Liver Disease Foundation, Echosens, Genfit, Gilead, GSK, Hepion, Hepta Bio, Hightide, HistoIndex, Intercept, Madrigal, Medpace, NGM Bio, Northsea, Novartis, Novo Nordisk, Perspectum, Poxel, Sagimet, Sonic Incytes, Terns and Viking; and is the owner of Pinnacle Clinical Research. R.T. is an employee and stockholder at Madrigal Pharmaceuticals. G.W.N. reports advisory/consulting fees from Boehringer Ingelheim; grant/research support from Madrigal Pharmaceuticals; and speaker’s fees from Intercept Pharmaceuticals. K.J.L. reports grant/research support from Madrigal Pharmaceuticals. D.L. is an employee at Madrigal Pharmaceuticals. S.E.M. reports grant/research support from Madrigal Pharmaceuticals; owns stock in Madrigal Pharmaceuticals. N.A. reports grant/research support from 89Bio, AbbVie/Allergan, Akero, Better Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Corcept, DSM, Galectin, Genentech, Genfit, Gilead, Hepagene, Healio, Intercept, Inventiva, Ionis, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking and Zydus; speaker’s fees from AbbVie/Allergan, Alexion, Echosens, Eisai, Exelixis, Gilead, Intercept, Perspectum, Salix and Theratechnologies; Consultant for AbbVie/Allergan, Echosens, Fibronostics, Gilead, Intercept, Madrigal, Novo Nordisk, Perspectum, Pfizer and Zydus. M.R.B. reports grant/research support from Carmot Therapeutics, Corcept Therapeutics, Madrigal Pharmaceuticals, Metacrine, NGM Biopharmaceuticals, Pinnacle Clinical Research, ProSciento and Siemens Healthineers; and advisory/consulting fees from Medpace.